Hadar Kolb

Dr. Hadar Kolb

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2021 in Annals of Neurology
Verified
Journal Article
Open access
PDF file
HKHadar Kolb
Hadar Kolb
MAMartina Absinta
Martina Absinta
EBErin S. Beck
Erin S. Beck
SHSeung‐Kwon Ha
Seung‐Kwon Ha
YSYeajin Song
Yeajin Song
DRDaniel Reich
Daniel Reich
Objective: To noninvasively assess myelin status in chronic white matter lesions of multiple sclerosis (MS), we developed and evaluated a simple classification scheme based on T1 relaxation time maps derived from 7‐tesla postmortem and in vivo MRI.Methods: Using the MP2RAGE MRI sequence, we classified 36 lesions from 4 postmortem MS brains as “long‐T1,” “short‐T1,” and “mixed‐T1” by visual comparison to neocortex. Within these groups, we compared T1 times to histologically derived measures of myelin and axons. We performed similar analysis of 235 chronic lesions with known date of onset in 25 MS cases in vivo and in a validation cohort of 222 lesions from 66 MS cases, investigating associations with clinical and radiological outcomes.Results: Postmortem, lesions classified qualitatively as long‐T1, short‐T1, and mixed‐T1 corresponded to fully demyelinated, fully remyelinated, and mixed demyelinated/remyelinated lesions, respectively (p ≤ 0.001). Demyelination (rather than axon loss) dominantly contributed to initial T1 prolongation. We observed lesions with similar characteristics in vivo, allowing manual classification with substantial interrater and excellent intrarater reliability. Short‐T1 lesions were most common in the deep white matter, whereas long‐T1 and mixed‐T1 lesions were prevalent in the juxtacortical and periventricular white matter (p = 0.02) and were much more likely to have paramagnetic rims suggesting chronic inflammation (p < 0.001). Older age at the time of lesion formation portended less remyelination (p = 0.007).Interpretation: 7‐tesla T1 mapping with MP2RAGE, a clinically available MRI method, allows qualitative and quantitative classification of chronic MS lesions according to myelin content, rendering straightforward the tracking of lesional myelination changes over time. ANN NEUROL 2021;90:612–626

14 September 2022 in NeuroImage: Clinical
Verified
Journal Article
Open access
HKHadar Kolb
Hadar Kolb
OAOmar Al-Louzi
Omar Al-Louzi
EBErin S. Beck
Erin S. Beck
PSPascal Sati
Pascal Sati
MAMartina Absinta
Martina Absinta
DRDaniel Reich
Daniel Reich
• MS white matter lesions are perivenular. The central vein sign (CVS) is a promising diagnostic biomarker with excellent sensitivity and specificity. • A subset of MS lesions, termed “chronic active,” shows persistent inflammatory demyelinating activity at the lesion edges. Their imaging correlate, “paramagnetic rim lesions” (PRL), can identify MS cases at risk for early disability accrual and progression. • PRL are specific for MS, however their diagnostic role requires more investigation. Pilot proof-of-concept clinical trials are now implementing PRL as outcome measures. • Imaging remyelination remains challenging, and no method has been accepted as a gold standard. At 7T, T1 times correlate with the degree of lesion myelination. • Cortical lesions are specific for MS and included in the current criteria for MS dissemination in space. Although cortical lesions have been associated with disease progression, their use is limited due to their difficult visualization in vivo, even with 7T MRI.

31 October 2018 in International Journal of Neuroscience
Verified
Journal Article
Closed access
AAAli Asmail
Ali Asmail
AKAnat Kesler
Anat Kesler
HKHadar Kolb
Hadar Kolb
VDVivian E. Drory
Vivian E. Drory
Arnon KarniArnon Karni
Arnon Karni
Background: A tri-modal distribution of age-at-onset emerged among females patients with myasthenia gravis (MG) in our database. This finding may be indicative of different gender-based disease mechanisms. Methods: We retrospectively reviewed the files of 127 MG patients for the clinical, serology, and thymus pathology according to their age at disease onset: ≤40 years (early-onset, EOMG), 40-70 years (intermediate-onset, IOMG) and >70 years (late-onset, LOMG). Results: EOMG was more common among females and IOMG was more common among males. Ocular MG was more common among the male MG patients with an IOMG. Patients with EOMG had lower rates of positive anti-acetylcholine receptor (anti-AChR). IOMG females, but not IOMG males, had lower rates of positive anti-AChR. IOMG and EOMG females had high rates of thymic hyperplasia, while EOMG males had high rates of thymoma. Comorbidity with autoimmune diseases was common among females with IOMG and LOMG. Conclusions: The prevalence of IOMG was the reason for the trend reversal of MG prevalence between genders. The clinical features of patients with IOMG differed between genders in the rates of positive anti-AChR, follicular hyperplasia of the thymus, and comorbidity with autoimmune diseases. This may suggest a different gender-based mechanism of immune intolerance towards AChR and other antigens.

Verified
Journal Article
Open access
PDF file
IBIdo Ben-Shalom
Ido Ben-Shalom
Arnon KarniArnon Karni
Arnon Karni
HKHadar Kolb
Hadar Kolb
The appearance of new disease-modifying therapies in multiple sclerosis (MS) has revolutionized our ability to fight inflammatory relapses and has immensely improved patients’ quality of life. Although remarkable, this achievement has not carried over into reducing long-term disability. In MS, clinical disability progression can continue relentlessly irrespective of acute inflammation. This “silent” disease progression is the main contributor to long-term clinical disability in MS and results from chronic inflammation, neurodegeneration, and repair failure. Investigating silent disease progression and its underlying mechanisms is a challenge. Standard MRI excels in depicting acute inflammation but lacks the pathophysiological lens required for a more targeted exploration of molecular-based processes. Novel modalities that utilize nuclear magnetic resonance’s ability to display in vivo information on imaging look to bridge this gap. Displaying the CNS through a molecular prism is becoming an undeniable reality. This review will focus on “molecular imaging biomarkers” of disease progression, modalities that can harmoniously depict anatomy and pathophysiology, making them attractive candidates to become the first valid biomarkers of neuroprotection and remyelination.

Verified
Journal Article
Open access
PDF file
MGMaya Golan
Maya Golan
AKAvivit Krivitsky
Avivit Krivitsky
KMKarin Mausner-Fainberg
Karin Mausner-Fainberg
MBMoshe Benhamou
Moshe Benhamou
IVIfat Vigiser
Ifat Vigiser
Arnon KarniArnon Karni
Arnon Karni
The effect of the inflammatory response on regenerative processes in the brain is complex. This complexity is even greater when the cause of the tissue damage is an autoimmune response. Multiple sclerosis (MS) is an immune-mediated disease in which demyelination foci are formed in the central nervous system. The degree of repair through oligodendrocyte regeneration and remyelination is insufficient. Ephrins are membrane-bound ligands activating tyrosine kinase signaling proteins that are known to have an inhibitory effect on oligodendrocyte regeneration. In this study, we examined the expression of ephrins on immune cells of 43 patients with relapsing-remitting (RR) MS compared to 27 matched healthy controls (HC). We found an increased expression of ephrin-A2, -A3 and -B3, especially on T cell subpopulations. We also showed overexpression of ephrins on immune cells of patients with RR-MS that increases the forward signaling pathway and that expression of ephrins on immune cells has an inhibitory effect on the differentiation of oligodendrocyte precursor cells (OPCs) in vitro. Our study findings support the concept that the immune activity of T cells in patients with RR-MS has an inhibitory effect on the differentiation capacity of OPCs through the expression and forward signaling of ephrins.

28 July 2022 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
LFLior Fuchs
Lior Fuchs
KMKarin Mausner-Fainberg
Karin Mausner-Fainberg
ALAnna Luban
Anna Luban
SASusanna Eva Asseyer
Susanna Eva Asseyer
MGMaya Golan
Maya Golan
Arnon KarniArnon Karni
Arnon Karni